NICE has concerns with the evidence submitted but Janssen insists the nasal spray is a cost-effective use of NHS resources
News
Sanofi, GSK launch early trial for COVID-19 vaccine
Over 400 participants are being enrolled in the Phase I/II study after promising preclinical safety and immunogenicity data
BMS bags US approval for Onureg
The oral therapy can be used as continued treatment for adults in first remission with acute myeloid leukaemia (AML)
EU OKs paediatric use of Gilead’s Epclusa
The decision allows use of the therapy in the EU in children as young as six years of age
NICE green light for immunotherapy Bavencio
Merck and Pfizer’s drug will now be available on the NHS in combination with axitinib as a first-line treatment for kidney cancer
Roche to launch SARS-CoV-2 rapid antigen test
The test can typically identify SARS-CoV-2 infection within 15 minutes
Kevzara fails in PhIII COVID-19 trial
Sanofi and Regeneron do not anticipate carrying out further research on Kevzara in COVID-19
UK launch for Novo’s new diabetes pill
Rybelsus is the world’s first and only oral GLP-1 receptor agonist
PhIII US trial for AZ’ coronavirus vaccine
Clinical development of AZD1222 is progressing globally with late-stage clinical trials ongoing in the UK, Brazil and South Africa
GSK, Vir Bio start study of COVID-19 antibody therapy
The Phase II/III COMET-ICE study will assess safety and efficacy of antibody treatment in preventing hospitalisation due to COVID-19
AZ’ Imfinzi bags new approval for lung cancer
The EC has cleared its use for the treatment of extensive-stage small cell lung cancer
COVID-19 has inspired Britons to take better care of their health
A survey by GSK Consumer Healthcare and Ipsos MORI also signals a shift towards self-education and reducing the burden on the NHS
US approves Roche’s new pan-tumour liquid biopsy test
FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta
NICE says the combination’s cost-effectiveness estimate is higher than what is considered acceptable for NHS use
NIHR, UKRI stream £8.4m into coronavirus studies
The studies aim to increase understanding on immune responses to SARS-CoV-2
